1.Spector NL, Xia W, 3rdBurris H , et al. . Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23: 2502–2512.
2.Slamon DJ, Leyland-Jones B, Shak S, et al. . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001; 344: 783–792.
3.DiLeo A, Gomez H, Aziz Z, et al. . Lapatinib with paclitaxel versus paclitaxel as first-line treatment for patienst with metastatic breast cancer: a phase III randomized, double-blind study in 580 patients. Proc Am Soc Clin Oncol Abs 2007; Abs 1011.
4.Paez JG, Janne PA, Lee JC, et al. . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500.
5.Yu K, Toral-Barza L, Discafani C, et al. . mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249–258.
6.Chow LWC, Shun Y, Jassem J, et al. . Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl 1); Abs 6091.
7.Johnston SRD. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in Breast Cancer. Clin Cancer Res 2006; 12: 1061s–1068s.
8.Nicholson RI, McClelland RA, Robertson JF, et al. . Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999; 6: 373–387.
9.Miller KD, Chap LI, Holmes FA, et al. . Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792–799.
10.Geyer CE, Forster J, Lindquist D, et al. . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355 (26): 2733–2743.
11.Braun S, Pantel K, Muller P, et al. . Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525–533.
12.Braun S, Kentenich C, Janni W, et al. . Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000; 18: 80–86.
13.Bozionellou V, Mavroudis D, Perraki M, et al. . Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004; 10: 8185–8194.
14.Romond EH, Perez EA, Bryant J, et al. . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–1684.